Brief: Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial

Q32 Bio

16/04/2025 12:07

April 16 (Reuters) - Q32 Bio Inc QTTB.O:

Q32 BIO DOSES FIRST PATIENTS IN BOTH PART A OPEN-LABEL EXTENSION AND PART B OF SIGNAL-AA PHASE 2A TRIAL EVALUATING BEMPIKIBART IN ALOPECIA AREATA

Q32 BIO INC - SIGNAL-AA PART B TOPLINE DATA READOUT ON-TRACK FOR 1H'26

Q32 BIO INC - EXPECTS SIGNAL-AA PART B DATA IN 1H'26

Source text: ID:nPn76h8Wya

Further company coverage: QTTB.O

 ((Reuters.Briefs@thomsonreuters.com;))